Weight loss drugs such as Ozempic and Wegovy, part of the GLP-1 receptor agonist family, have been hailed as groundbreaking solutions for obesity and type 2 diabetes. However, a study presented at the San Antonio Breast Cancer Symposium has raised questions about the safety of these medications during cancer treatment. The research observed that patients taking GLP-1 drugs while undergoing treatment for triple-negative breast cancer (TNBC) experienced poorer outcomes compared to those not on these medications.
Specifically, only 28% of women on GLP-1 drugs like Ozempic were cancer-free after treatment, compared to 63% of those not taking the drugs. Researchers found traces of GLP-1 agonists in tumor and immune cells, raising concerns that these medications might interfere with chemotherapy and immunotherapy. However, Dr. Bethania Santos, who led the study, emphasized that it does not confirm that GLP-1 drugs are harmful, but it highlights the need for careful consideration during therapy.
Could GLP-1 Drugs Impact Tumor Treatment Responsiveness?
GLP-1 agonists like Ozempic work by regulating hormones like ghrelin, leptin, and insulin, which control hunger and metabolism. While these effects contribute to weight loss, they may also influence cancer biology. The study noted that GLP-1 agonists might make tumor cells less responsive to standard cancer treatments.
Some experts believe the findings could be due to other factors, such as the underlying health of patients using GLP-1 drugs. Professor Neil lyengar of the Memorial Sloan Kettering Cancer Center pointed out that many participants on GLP-1 drugs were also taking multiple medications for advanced diabetes. “It’s more likely their underlying condition increased the risk of recurrence, rather than the drugs directly affecting treatment efficacy,” he said.
Dr. Santos agreed, suggesting the study underscores the complexity of cancer treatment and metabolic health. Further research is needed to clarify these findings, particularly given the beneficial role of drugs like Ozempic in reducing obesity—a known risk factor for 13 types of cancer, including breast cancer.
Read More: The ‘Ozempic Diet:’ Can Certain Foods Simulate The Effect of Semaglutide?
Promise and Caution for GLP-1 Drugs in Cancer Care
Despite the concerns raised, GLP-1 drugs have shown promise in cancer prevention. Research has linked these medications to a reduced risk of obesity-associated cancers, including colorectal, pancreatic, and ovarian cancers. A study published in JAMA Network Open found that GLP-1 users were less likely to develop 10 out of 13 obesity-related cancers compared to patients on insulin.
Breast cancer is a notable exception. While some GLP-1 drugs (like Ozempic) reduce general cancer risks, no significant reduction was observed for breast cancer, and questions remain about their effects during active treatment.
Experts urge caution and tailored approaches. “The weight loss benefits could reduce cancer recurrence after treatment, but we don’t yet know enough to recommend these drugs during therapy,” said Dr. Liz O’Riordan, a breast cancer specialist. Dr. Santos echoed these sentiments, noting, “Patients should inform their oncologists about any weight loss medications they are taking to ensure safe and effective treatment strategies”.
The Need for Further Research
As weight loss drugs gain popularity, their role in cancer prevention and treatment remains a critical area of study. While the findings of this study are unsettling, they do not provide definitive evidence of harm. The relationship between GLP-1 drugs and cancer therapy is likely multifaceted, involving factors such as metabolic health, weight loss, and drug interactions.
Dr. Santos and other experts emphasize the need for more comprehensive clinical trials to understand how these medications affect cancer patients. Until then, both patients and physicians should weigh the risks and benefits carefully.
GLP-1 agonists like Ozempic and Wegovy represent a significant advancement in obesity and metabolic health management, with potential benefits for cancer prevention. However, their use during cancer treatment warrants caution. As the science evolves, personalized care and open communication between patients and oncologists will be essential to navigate these complexities.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
Read More: What is ‘Ozempic Finger’? Users Complain About Little-Known Side Effect of Popular Drug